Stéphanie Chièze

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo et al. · Journal of Clinical Oncology · 2005 · 99 citations · Full text

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

Lise Roca, Véronique Dièras, Henri Roché et al. · Breast Cancer Research and Treatment · 2013 · 68 citations

Fcgr3a Gene Polymorphisms, Cardiovascular Disease, Genetic Epidemiology +9

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

Werner Hilgers, Sandrine Faivre, Stéphanie Chièze et al. · Investigational New Drugs · 2006 · 16 citations

Oncology, Medicine, Pharmacokinetic Study +8

Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer

Hugues Bourgeois, Aurélie Ferru, Alain Lortholary et al. · American Journal of Clinical Oncology · 2006 · 11 citations